Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
This is a phase II, multicenter, single-arm study in which the safety and efficacy of X-396(Ensartinib) will be assessed in adult Chinese patients with ALK-positive(rearrangement) non-small cell lung cancer previously treated with crizotinib. Approximately 144 patients with locally advanced or metastatic NSCLC which carry ALK -rearrangement will be enrolled in the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer.
Evidence of positive ALK.
Patients must have demonstrated progression during or after crizotinib treatment.
Age 18 years or older at the time of informed consent.
Eastern cooperative oncology group performance status (ECOG PS) of 0-2
Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1).
Asymptomatic CNS metastases do not require the use of steroids or anticonvulsants.
Willingness and ability to comply with the trial and follow-up procedures.
Ability to understand the nature of this trial and give written informed consent.
You may not be if
Prior use of ALK TKIs with the exception of crizotinib.
Patients currently receiving cancer system therapy.
Use of an investigational drug within 4 weeks prior to the first dose of study drug.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
Patients with a known allergy or delayed hypersensitivity reaction to drugs.